Donaldson rises 2.9% after CEO presentation and new filtration product coincide with the move

What happened

Donaldson (DCI) rose 2.9% on November 2, 2026, after a presentation by President and CEO Rich Lewis and the launch of a new sterile filtration platform coincided with the move. The CEO presentation highlighted recurring aftermarket revenue, investments in technology and expansion in industrial and life sciences applications, and referenced an $830M Facet deal, according to MarketBeat. Business Wire reported the company introduced Alpha‑Pore™, a new sterile filtration platform designed to extend filter service life while preserving critical process performance for use in critical applications. Volume was elevated as the stock traded 1.4 times its 20-day average while the S&P 500 fell 0.5% that day.

How big was the move

The stock rose 2.9%, a move that was 2.4 times a typical daily move for this stock and 1.5 percentage points better than the Industrials sector median, which rose 1.3% on the day. Over the last five sessions the stock fell 0.2% while the S&P 500 over five sessions fell 1.8%, a contrast that points to both market and company-specific drivers. Trading volume 1.4 times its 20-day average showed stronger-than-normal investor attention, and a beta of 0.73 indicates the stock tends to move less than the market. In the past five years the stock had 37 sessions with a gain of at least 2.9%; twenty trading days later the median result was a decline of 0.5%, and 18 of 37 were higher.

The technical picture

The stock was trading below its short, medium and long-term averages: it was 1.5% below its 20-day moving average, 3.1% below its 50-day moving average and 5.8% below its 200-day moving average. The 50-day average was below the 200-day average, a sign of a weak longer-term trend. Relative Strength Index (14 days) stood at 44, in a neutral range between 30 and 70. The share price was 24.4% below the 52-week high; it fell 3.7% over one month and fell 13.1% over three months, while over one year it rose 2.0%. Sixty-day volatility was 19% annualized, lower than 80% of its own readings over five years, suggesting recent price moves were steadier than in most prior periods.

Fundamentals and valuation

For the four quarters through July 31, 2026, revenue was $3.89 billion, which grew 5.3% from a year earlier and compared with growth of 4.4% one quarter earlier. Diluted earnings per share were $3.85, which rose 26.2% from a year earlier. Gross margin was 34.6% (a year earlier: 34.8%) and operating margin was 15.4% (a year earlier: 13.4%), while free-cash-flow margin was 11.0% and return on invested capital was 14.3%. The balance sheet showed net debt of 1.8 times EBITDA and share count over one year decreased by 0.2%.

Valuation metrics show the stock at 22.2 times trailing earnings, lower than 52% of its own readings over the past five years (five-year median: 22.6 times earnings). On a forward basis the stock trades at 19.7 times expected earnings and has a free-cash-flow yield of 4.4%. Market value stands at $9.61 billion. PromtFinance scores mix strengths and weaknesses. The company scored 61 for Value (Neutral), 54 for Growth (Neutral) and 68 for Quality (Positive). It scored 38 for Momentum (Weak) and 19 for Revisions (Very weak), while Stability sat at 92 (Exceptional). That profile underscores steady cash generation and quality metrics alongside weak revision trends and limited momentum.

Earnings and analyst expectations

Donaldson’s last report arrived on August 26, 2026, when earnings per share were $1.15 against $1.13 expected, 1.8% above estimates. The company has recorded two consecutive quarters beating estimates; however, the average surprise over the last four reports was 0.8% below estimates. The typical two-day reaction after recent reports was the stock rose 0.3%. The next report is scheduled for December 3, 2026. Fourteen analysts cover the stock; the consensus rating is Hold, with 36% of analysts giving a Share rating the stock Buy or Strong Buy and a consensus price target of $96.50, which is 13.1% above the closing price.

What to watch

• December 3, 2026 — next earnings report
• August 26, 2026 — last report: earnings per share of $1.15 against $1.13 expected, 1.8% above estimates
• Presentation referenced an $830M Facet deal (reported by MarketBeat)
• Introduction of Alpha‑Pore™ sterile filtration platform (reported by Business Wire)
• Consensus price target $96.50, 13.1% above the closing price